

Vivir con VIH: comprender la experiencia de los pacientes y valorar la ciencia
Actividad #1. Planee su propio curso

Referencias

AIDSVu. AIDSVu map. Accessed February 4, 2022. <https://map.aidsvu.org/map>

APA. HIV/AIDS and socioeconomic status. Updated 2010. Accessed March 7, 2022. <https://www.apa.org/pi/ses/resources/publications/hiv-aids>

Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. *Lancet HIV*. 2018;5(8):e438-e447. doi:10.1016/S2352-3018(18)30132-2

Bogart LM, Mutchler MG, McDavitt B, et al. A randomized controlled trial of rise, a community-based culturally congruent adherence intervention for Black Americans living with HIV. *Ann Behav Med*. 2017;51(6):868-878. doi:10.1007/s12160-017-9910-4

Braun HM, Candelario J, Hanlon CL, et al. Transgender women living with HIV frequently take antiretroviral therapy and/or feminizing hormone therapy differently than prescribed due to drug-drug interaction concerns. *LGBT Health*. 2017;4(5):371-375. doi:10.1089/lgbt.2017.0057

Brawner BM, Guthrie B, Stevens R, Taylor L, Eberhart M, Schensul JJ. Place still matters: racial/ethnic and geographic disparities in hiv transmission and disease burden. *J Urban Health*. 2017;94(5):716-729. doi:10.1007/s11524-017-0198-2

Cabenuva. Prescribing information. ViiV Healthcare; 2022. Accessed May 10, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf

Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naïve adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr*. 2020;83(3):310-318. doi:10.1097/QAI.0000000000002275

Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naïve adults with HIV-1 infection. *AIDS*. 2022;36(1):39-48. doi:10.1097/QAD.0000000000003070

CDC. A guide to taking a sexual history. Updated January 14, 2022. Accessed February 4, 2022. <https://www.cdc.gov/std/treatment/SexualHistory.pdf>

CDC. Cultural competence in health and human services. Updated September 2021. Accessed March 14, 2022. <https://npin.cdc.gov/pages/cultural-competence>

CDC. Defining health disparities. Updated September 14, 2020. Accessed March 3, 2022. <https://www.cdc.gov/nchhstp/healthdisparities/>

CDC. Effectiveness of prevention strategies to reduce the risk of acquiring or transmitting HIV. Updated December 2021. Accessed March 15, 2022. <https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html>

CDC. HIV and STD criminalization laws. Updated December 2021. Accessed March 15, 2022.

<https://www.cdc.gov/hiv/policies/law/states/exposure.html>

CDC. HIV prevention. Updated June 2021. Accessed March 15, 2022.

[https://www.cdc.gov/hiv/basics/prevention.html#:~:text=You%20can%20use%20strategies%20such,%20Dexposure%20prophylaxis%20\(PEP\)](https://www.cdc.gov/hiv/basics/prevention.html#:~:text=You%20can%20use%20strategies%20such,%20Dexposure%20prophylaxis%20(PEP))

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.

<https://www.cdc.gov/nchhstp/atlas/index.htm>

CDC. Telling others. Updated May 2021. Accessed March 15, 2022.

<https://www.cdc.gov/hiv/basics/livingwithhiv/telling-others.html>

Clark H, Babu AS, Wiewel EW, Opoku J, Crepaz N. Diagnosed HIV infection in transgender adults and adolescents: results from the National HIV Surveillance System, 2009-2014. *AIDS Behav*. 2017;21(9):2774-2783. doi:10.1007/s10461-016-1656-7

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS*. 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. *Fed Pract*. 2016;33(Suppl 3):24S-30S.

Earnshaw VA, Bogart LM, Dovidio JF, Williams DR. Stigma and racial/ethnic HIV disparities: Moving toward resilience. *Stigma and Health*. 2015;1(S):60-74. doi:10.1037/2376-6972.1.S.60

Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. *JAMA*. 2019;321(9):844-845. doi:10.1001/jama.2019.1343

Grove M, Brown LL, Knudsen HK, Martin EG, Garner BR. Employing telehealth within HIV care: advantages, challenges, and recommendations. *AIDS*. 2021;35(8):1328-1330. doi:10.1097/QAD.0000000000002892

Hemmige V, McFadden R, Cook S, Tang H, Schneider JA. HIV prevention interventions to reduce racial disparities in the United States: a systematic review. *J Gen Intern Med*. 2012;27(8):1047-67. doi:10.1007/s11606-012-2036-2

Henkhaus ME, Hussen SA, Brown DN, et al. Barriers and facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia. *PLoS One*. 2021;16(3):e0247328. doi:10.1371/journal.pone.0247328

HRSA RWHAP. Available care & services. Updated February 2022. Accessed March 14, 2022.

<https://ryanwhite.hrsa.gov/hiv-care/services>

HRSA RWHAP. Program parts & initiatives. Updated February 2022. Accessed March 14, 2022.

<https://ryanwhite.hrsa.gov/about/parts-and-initiatives>

Lo CC, Runnels RC, Cheng TC. Racial/ethnic differences in HIV testing: An application of the health services utilization model. *SAGE Open Med*. 2018;6:2050312118783414. doi:10.1177/2050312118783414

Nan C, Shaefer M, Urbaityte R, et al. Abacavir use and risk for myocardial infarction and cardiovascular events: pooled analysis of data from clinical trials. *Open Forum Infect Dis*. 2018;5(5):ofy086. doi:10.1093/ofid/ofy086

Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. *Lancet HIV*. 2020;7(6):e389-e400. doi:10.1016/S2352-3018(20)30099-0

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. *AIDS*. 2019;33(9):1411-1420. doi:10.1097/QAD.0000000000002227

Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet*. 2019;393(10189):2428-2438. doi:10.1016/s0140-6736(19)30418-0

Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the hiv-positive partner is using suppressive antiretroviral therapy. *JAMA*. 2016;316(2):171-81. doi:10.1001/jama.2016.5148

Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis*. 2020;71(6):1379-1389. doi:10.1093/cid/ciz999

Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019;6(6):e364-e372. doi:10.1016/S2352-3018(19)30080-3

Sullivan PS, Woodyatt C, Koski C, et al. A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSvu Public Data Resource. *J Med Internet Res*. 2020;22(10):e23173. doi:10.2196/23173

Taggart T, Grewe ME, Conserve DF, Gliwa C, Roman Isler M. Social media and HIV: a systematic review of uses of social media in HIV communication. *J Med Internet Res*. 2015;17(11):e248. doi:10.2196/jmir.4387

Thompson MA, Horberg MA, Agwu AL, et al. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis*. 2021;73(11):e3572-e3605. doi:10.1093/cid/ciaa1391

Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV*. 2020;7(10):e666-e676. doi:10.1016/S2352-3018(20)30241-1

White E, Globerman J. Impact of community-based organizations for people living with HIV. Ontario HIV Treatment Network. Updated October 2015. Accessed March 9, 2022. <https://www.ohtn.on.ca/rapid-response-97-impact-of-community-based-organizations-for-people-living-with-hiv-2/>

Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019;6(6):e355-e363. doi:10.1016/S2352-3018(19)30077-3

Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at: AIDS 2020 - 23rd Journal of the International AIDS Society; 2020; Virtual. https://www.natap.org/2020/IAC/IAC_112.htm